Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Combination of pembrolizumab with electrochemotherapy in cutaneous metastases from melanoma : a comparative retrospective study from the InspECT and Slovenian Cancer Registry
Avtorji:ID Campana, Luca Giovanni (Avtor)
ID Perić, Barbara (Avtor)
ID Mascherini, Matteo (Avtor)
ID Spina, Romina (Avtor)
ID Kunte, Christian (Avtor)
ID Kis, Erika (Avtor)
ID Rozsa, Petra (Avtor)
ID Quaglino, Pietro (Avtor)
ID Čemažar, Maja (Avtor)
ID Omerzel, Maša (Avtor)
ID Serša, Gregor (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2072-6694/13/17/4289
 
.pdf PDF - Predstavitvena datoteka, prenos (701,05 KB)
MD5: F2DD7681624B085555665A4B6B6F5059
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Electrochemotherapy (ECT) is an effective locoregional therapy for cutaneous melanoma metastases and has been safely combined with immune checkpoint inhibitors in preliminary experiences. Since ECT is known to induce immunogenic cell death, its combination with immune checkpoint inhibitors might be beneficial. In this study, we aimed to investigate the effectiveness of ECT on cutaneous melanoma metastases in combination with pembrolizumab. We undertook a retrospective matched cohort analysis of stage IIIC%IV melanoma patients, included in the International Network for sharing practices of ECT (InspECT) and the Slovenian Cancer Registry. We compared the outcome of patients who received the following treatments: (a) pembrolizumab alone, (b) pembrolizumab plus ECT, and (c) ECT. The groups were matched for age, sex, performance status, and size of skin metastases. The local objective response rate (ORR) was higher in the pembrolizumab-ECT group than in the pembrolizumab group (78% and 39%, p < 0.001). The 1 year local progression-free survival (LPFS) rates were 86% and 51% (p < 0.001), and the 1 year systemic PFS rates were 64% and 39%, respectively (p = 0.034). The 1 year overall survival (OS) rates were 88% and 64%, respectively (p = 0.006). Our results suggest that skin-directed therapy with ECT improves superficial tumor control in melanoma patients treated with pembrolizumab. Interestingly, we observed longer PFS and OS in the pembrolizumab-ECT group than in the pembrolizumab group. These findings warrant prospective confirmation.
Ključne besede:electrochemotherapy, metastatic melanoma, skin metastases
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:25.08.2021
Založnik:MDPI
Leto izida:2021
Št. strani:str. 4289-1-4289-13
Številčenje:Vol. 13, no. 17
PID:20.500.12556/DiRROS-15616 Novo okno
UDK:616.5
ISSN pri članku:2072-6694
DOI:10.3390/cancers13174289 Novo okno
COBISS.SI-ID:74755075 Novo okno
Avtorske pravice:by Authors
Opomba:Nasl. z nasl. zaslona; Opis vira z dne 31. 8. 2021;
Datum objave v DiRROS:10.10.2022
Število ogledov:971
Število prenosov:546
Metapodatki:XML DC-XML DC-RDF
:
CAMPANA, Luca Giovanni, PERIĆ, Barbara, MASCHERINI, Matteo, SPINA, Romina, KUNTE, Christian, KIS, Erika, ROZSA, Petra, QUAGLINO, Pietro, ČEMAŽAR, Maja, OMERZEL, Maša in SERŠA, Gregor, 2021, Combination of pembrolizumab with electrochemotherapy in cutaneous metastases from melanoma : a comparative retrospective study from the InspECT and Slovenian Cancer Registry. Cancers [na spletu]. 2021. Vol. 13, no. 17, p. 4289-1-4289–13. [Dostopano 13 marec 2025]. DOI 10.3390/cancers13174289. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=15616
Kopiraj citat
  
Objavi na:Bookmark and Share


Iščem podobna dela...Prosim, počakajte...
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Cancers
Skrajšan naslov:Cancers
Založnik:MDPI
ISSN:2072-6694
COBISS.SI-ID:517914137 Novo okno

Gradivo je financirano iz projekta

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P3-0003-2015
Naslov:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:08.10.2022

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:elektrokemoterapija, metastatski melanom, kožne metastaze


Nazaj